The parvovirus-induced DNA damage response and cell cycle perturbations
细小病毒诱导的 DNA 损伤反应和细胞周期扰动
基本信息
- 批准号:9028668
- 负责人:
- 金额:$ 37.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-12-01 至 2020-11-30
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAreaBindingBiological ModelsCDC2 Protein KinaseCell CommunicationCell CycleCell Cycle ArrestCell Cycle RegulationCell physiologyCellsCellular biologyComplexDNADNA DamageDNA StructureDNA VirusesDNA biosynthesisDNA-Directed DNA PolymeraseDisabled PersonsDiseaseEnvironmentG2 PhaseG2/M ArrestGenomeHumanInfectionKnowledgeLicensing FactorLigaseMediationMediator of activation proteinMice Minute VirusMitoticMusMutagensNuclearParvovirinaeParvovirusParvovirus InfectionsPlayProcessProteinsPublishingRNAReplication LicensingResearch DesignRoleSignal TransductionSingle-Stranded DNASourceStimulusSystemTP53 geneTimeVertebrate VirusesViralViral GenomeViral Nonstructural ProteinsViral PathogenesisVirusVirus DiseasesVirus ReplicationWorkbasecell typecyclin B1gene therapyinsightmouse genomenovelpathogenpreventprogramspublic health relevancerepairedresponseubiquitin-protein ligase
项目摘要
DESCRIPTION (provided by applicant): Replication of the parvovirus minute virus of mice (MVM) induces a sustained cellular DNA damage response (DDR) which the virus then exploits to enhance its infection in host cells. An essential aspect of the MVM-induced DDR is the establishment of a potent G2/M arrest. Although p53 remains activated, p21 is degraded and ATR/Chk1 signaling is disabled. We find that a surprising p21- and Chk1-independent cell cycle block is established via a novel mechanism that results in the significant, specific depletion of cyclin B1 and its encoding RNA, which precludes cyclin B1/CDK1 complex function thus preventing mitotic entry. The Parvovirinae are small non-enveloped icosahedral viruses that are important pathogens in many animal species including humans. They are the only known viruses of vertebrates that contain single-stranded linear DNA genomes, and they continually present novel replicative DNA structures to cells during infection. This application proposes to further examine how MVM exploits the cellular DDR to prepare the nuclear environment for effective parvovirus takeover. The following aims are based on recently published findings: Aim I. How, and for what purpose, does the MVM-induced DDR cause re-localization of the CRL4Cdt2 E3 ubiquitin ligase to APAR bodies? Efficient MVM replication requires the CRL4Cdt2 E3 ubiquitin ligase-targeted depletion of p21 to prevent its inhibitory interaction with PCNA, an essential co-factor for DNA polymerase , which replicates the MVM genome. This ligase also has other important targets involved in DNA replication. We propose to further characterize the status and localization of the components of the ligase complex within viral replication centers; characterize the mechanism by which p21 is depleted, Cdt1 is spared, and how this facilitates infection; and investigate potential additional roles for the ligase during infection. Aim II. How, and for what purpose, is ATR signaling disabled during the MVM-induced DDR? Neither Chk1, a downstream target of ATR and normally an important mediator of cell cycle arrest, nor ATR itself, is activated during MVM infection, even though viral genomes bearing bound RPA - normally a potent trigger of ATR activation - accumulate in viral replication centers. It is now clear that ATR signaling is actively disabled following establishment of the MVM-induced DDR. We propose to investigate the means by which ATR is disabled, and the purpose its disabling serves during infection. Aim III. How, and for what purpose, does the MVM-induced DDR cause depletion of cyclin B1? The MVM-induced p21- and Chk1-independent cell cycle arrest proceeds via a process unlike that seen in response to other DNA-damaging agents or other virus infections: it results in a dramatic depletion of cyclin B1 and its encoding RNA which precludes mitotic entry. We propose to determine the mechanism by which cyclin B1 RNA is depleted in infected cells, whether there is a role for the viral nonstructural proteins within the context of an ongoing DDR, and to determine the purpose this depletion serves during infection.
描述(通过应用提供):小鼠(MVM)细小病毒分钟病毒的复制会诱导持续的细胞DNA损伤反应(DDR),然后该病毒利用该反应来增强其在宿主细胞中的感染。 MVM引起的DDR的一个重要方面是建立潜在的G2/m逮捕。尽管p53仍然激活,但p21被降解,并且禁用了ATR/CHK1信号。我们发现,通过一种新型机制建立了令人惊讶的P21-和CHK1独立的细胞周期块,该机制导致细胞周期蛋白B1的显着,特定的部署及其编码RNA,从而排除了Cyclin B1/CDK1复杂函数,从而防止了有丝分裂的进入。 Parvovirinae是小的非发育二十体病毒,在包括人类在内的许多动物物种中都是重要的病原体。它们是唯一含有单链线性DNA基因组的脊椎动物病毒,并且在感染过程中不断向细胞呈现新型的复制DNA结构。该应用建议进一步研究MVM如何探讨细胞DDR,以准备有效的细节性核环境。以下目的基于最近发表的发现:AIM I. MVM诱导的DDR如何以及出于什么目的会导致CRL4CDT2 E3泛素连接酶的重新定位到Apar身体?有效的MVM复制需要CRL4CDT2 E3泛素连接酶靶向P21的部署,以防止其与PCNA的抑制相互作用,PCNA是DNA聚合酶的必不可少的co contactor,这是复制MVM基因组的必不可少的。该连接酶还具有其他重要的DNA复制靶标。我们建议进一步表征病毒复制中心中连接酶复合物成分的状态和定位;表征p21耗尽的机制,cdt1被保存,以及如何促进感染。并研究感染过程中连接酶的潜在其他作用。目标II。在MVM诱导的DDR期间,ATR信号传导如何,出于什么目的? CHK1是ATR的下游靶标,通常是细胞周期停滞的重要介质,也没有ATR本身在MVM感染过程中被激活,即使具有结合RPA的病毒基因组(通常是ATR激活的潜在触发) - 在病毒复制中心积聚。现在很明显,在建立MVM诱导的DDR后,ATR信号被积极禁用。我们建议研究ATR被禁用的手段,以及其在感染过程中残疾人的目的。目标三。 MVM诱导的DDR如何以及出于什么目的会导致细胞周期蛋白B1的耗竭? MVM诱导的P21-和CHK1非依赖性细胞周期停滞通过一个过程与其他响应其他DNA受损剂或其他病毒感染不同的过程进行:它导致细胞周期蛋白B1及其编码RNA的急剧部署,从而阻止了有丝分裂的进入。我们建议确定细胞周期蛋白B1 RNA在感染细胞中耗尽的机制,是否在持续的DDR的背景下病毒非结构性蛋白具有作用,并确定该部署在感染过程中的目的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID J. PINTEL其他文献
DAVID J. PINTEL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID J. PINTEL', 18)}}的其他基金
The parvovirus-induced DNA damage response and cell cycle perturbations
细小病毒诱导的 DNA 损伤反应和细胞周期扰动
- 批准号:
9185939 - 财政年份:2015
- 资助金额:
$ 37.97万 - 项目类别:
Adeno-associated Virus RNA Splicing and Polyadenylation
腺相关病毒 RNA 剪接和多聚腺苷酸化
- 批准号:
8466105 - 财政年份:2012
- 资助金额:
$ 37.97万 - 项目类别:
Adeno-associated Virus RNA Splicing and Polyadenylation
腺相关病毒 RNA 剪接和多聚腺苷酸化
- 批准号:
7009295 - 财政年份:2004
- 资助金额:
$ 37.97万 - 项目类别:
Adeno-associated Virus RNA Splicing and Polyadenylation
腺相关病毒 RNA 剪接和多聚腺苷酸化
- 批准号:
6847845 - 财政年份:2004
- 资助金额:
$ 37.97万 - 项目类别:
Adeno-associated Virus RNA Splicing and Polyadenylation
腺相关病毒 RNA 剪接和多聚腺苷酸化
- 批准号:
7760566 - 财政年份:2004
- 资助金额:
$ 37.97万 - 项目类别:
Adeno-associated Virus RNA Splicing and Polyadenylation
腺相关病毒 RNA 剪接和多聚腺苷酸化
- 批准号:
8016651 - 财政年份:2004
- 资助金额:
$ 37.97万 - 项目类别:
相似国自然基金
定向金属结合区域的倒捻子素类PDE4抑制剂:类药性优化及抗肺纤维化作用研究
- 批准号:22277019
- 批准年份:2022
- 资助金额:54.00 万元
- 项目类别:面上项目
定向金属结合区域的倒捻子素类PDE4抑制剂:类药性优化及抗肺纤维化作用研究
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
高光谱遥感与地面观测数据结合的区域甘蔗糖分估算研究
- 批准号:42105175
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
ERβ结合区域遗传变异与结直肠癌发病风险的机制研究
- 批准号:
- 批准年份:2020
- 资助金额:57 万元
- 项目类别:面上项目
基于“区域资源高效协同机制”作用的医养结合养老社区中医疗功能空间配置研究
- 批准号:
- 批准年份:2020
- 资助金额:58 万元
- 项目类别:面上项目
相似海外基金
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
- 批准号:
10751872 - 财政年份:2024
- 资助金额:
$ 37.97万 - 项目类别:
Deciphering the role of VTA dopaminergic signaling in memory consolidation during sleep
解读 VTA 多巴胺能信号在睡眠期间记忆巩固中的作用
- 批准号:
10677962 - 财政年份:2023
- 资助金额:
$ 37.97万 - 项目类别:
Develop an engineered Cas effector for in vivo cell-targeted delivery in the eye to treat autosomal dominant BEST disease
开发工程化 Cas 效应器,用于眼内体内细胞靶向递送,以治疗常染色体显性 BEST 疾病
- 批准号:
10668167 - 财政年份:2023
- 资助金额:
$ 37.97万 - 项目类别:
Illumination of TAAR2 Location, Function and Regulators
TAAR2 位置、功能和调节器的阐明
- 批准号:
10666759 - 财政年份:2023
- 资助金额:
$ 37.97万 - 项目类别:
Involvement of dopamine signaling in chronic pain-induced negative affective state and nicotine use comorbidity
多巴胺信号传导参与慢性疼痛引起的负面情感状态和尼古丁使用合并症
- 批准号:
10662951 - 财政年份:2023
- 资助金额:
$ 37.97万 - 项目类别: